SLC51B
Organic solute transporter subunit beta
Also known as: OSTB_HUMAN, OSTbeta
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q86UW2
- Gene
- SLC51B
- Ensembl
- ENSG00000186198
- Chromosome
- 15
- Canonical length
- 128 aa
- Protein class
- Disease related genes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted membrane proteins, Transporters
- Subcellular location
- Vesicles,Mitochondria
OverviewNCBI Gene
Predicted to enable bile acid transmembrane transporter activity and protein heterodimerization activity. Involved in bile acid secretion. Located in basolateral plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
128 residues, UniProt reviewed canonical sequence.
>Q86UW2|SLC51B
1 MEHSEGAPGD PAGTVVPQEL LEEMLWFFRV EDASPWNHSI LALAAVVVII SMVLLGRSIQ
61 ASRKEKMQPP EKETPEVLHL DEAKDHNSLN NLRETLLSEK PNLAQVELEL KERDVLSVFL
121 PDVPETESLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SLC51B can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.56
- Highest tissue expression
- 101 nTPM
Expression across tissuesHPA
Tissue
- small intestine: 101 nTPM
- duodenum: 82 nTPM
- cervix: 39 nTPM
- colon: 39 nTPM
- rectum: 28 nTPM
- kidney: 18 nTPM
Single-cell type
- enterocytes: 680 nCPM
- colonocytes: 336 nCPM
- epididymal efferent duct absorptive cells: 241 nCPM
- enteric transient amplifying cells: 89 nCPM
- late primary spermatocytes: 72 nCPM
- early spermatids: 54 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- thalamus: 30 nTPM
- midbrain: 29 nTPM
- medulla oblongata: 22 nTPM
- spinal cord: 19 nTPM
- hypothalamus: 19 nTPM
- pons: 19 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SLC51B.
Disease | AllUniProt
Conditions SLC51B is implicated in, by any mechanism.
- Bile acid malabsorption, primary, 2 (PBAM2) MIM:619481
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 103 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Cholestasis
- Diarrhea
- Bile acid malabsorption, primary, 2
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.36
- gnomAD pLI
- 0.24
- gnomAD missense Z
- 0.46
- DepMap mean gene effect
- -0.03
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- bile acid and bile salt transport
- bile acid secretion
- positive regulation of glycoprotein biosynthetic process
- positive regulation of protein exit from endoplasmic reticulum
- positive regulation of protein targeting to membrane
- regulation of protein stability
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Organic solute transporter subunit beta
- Organic solute transporter beta subunit
- Organic solute transporter subunit beta protein
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SLC51B in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SLC51B as an antibody target. Whether an autoantibody or antibody against SLC51B could matter depends on whether native SLC51B is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SLC51B is annotated at the cell surface, where native SLC51B is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label SLC51B as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...